Category: Abbott Laboratories
Abbott Labs' earnings sink more than 30% in its 1st quarter of 2014 as special charges eat up its bottom line.
Illinois-based Abbott (NYSE:ABT) managed to beat analysts' expectations for its 1st quarter, even as sales waned and special charges eroded its bottom line.
Healthcare giant Abbott completes enrollment in 3 clinical trials evaluating its novel dissolving, drug-eluting scaffold in patients with blocked heart vessels.
Illinois healthcare titan Abbott (NYSE:ABT) closed 3 clinical trials after enrolling about 2,800 patients in studies of the company's dissolving Absorb drug-eluting scaffold.
Here's a look at some of the top Wall Street stories for medical device companies this week.
, American College of Cardiology
, Arterial Remodeling Technologies
, Baxter International
, Edwards Lifesciences
, K-C Health Care
, Kimberly-Clark Worldwide Inc.
, Smith & Nephew
, Terumo Corp.
, Urologix Inc.
, Abbott Laboratories
Seven-year results from Boston Scientific's MADIT-CRT trial show long-term benefits for some patients with mild heart failure.
Some patients with mild heart failure show significant, long-term benefits from cardiac-resynchronization therapy, according to the 7-year results from Boston Scientific's (NYSE:BSX) MADIT-CRT clinical trial presented at the American College of Cardiology's annual meeting over the weekend.
Abbott says the FDA granted pre-market approval for its Supera stent for treating peripheral artery disease.
Abbott (NYSE:ABT) said the FDA granted pre-market approval for its Supera peripheral stent.
Abbott Park, Ill.-based Abbott said the stent is designed to conform to the shape of patients' blood vessels. The FDA approved the Supera device for treating occlusions in the superficial femoral artery and the proximal popliteal artery.
Baxter International says it plans to go the way of rivals Abbott and Covidien in splitting its pharmaceuticals and medical products businesses into separate companies.
Abbott Diabetes Care recalls FreeStyle and FreeStyle Flash blood glucose meters users over concerns that the devices may report erroneously low readings.
Updated March 17, 2014, at 4:30 pm. with comments from Abbott.